CClinicalTrials.gg
Sign In
CompletedNCT02425748Updated Sep 12, 2019

Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)

A Phase 1/2 interventional study of DC-CIK and γδ T Cell in Lung Cancer, sponsored by Fuda Cancer Hospital, Guangzhou. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-12.

Sponsored by Fuda Cancer Hospital, Guangzhou · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

In this study, effects of γδT cells on human non small lung cancer ( without EGFR mutation) in combination with tumor reducing surgery, for example cryosurgery going to be investigated.

Read the detailed description

Non small lung cancer will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as immunotherapy.

02

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • γδ T Cell, non small lung cancer, Without EGFR Mutation
03

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's enrollment of 40 is below the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

Fuda Cancer Hospital, Guangzhou is the lead sponsor of 113 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age:18-75
  2. Karnofsky performance status >50
  3. Diagnosis with non small lung tumors based on histology or the current accepted radiological measures.
  4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ Will receive cryosurgery, gd Tcells/ DC-CIK.
  5. Life expectancy: Greater than 3 months
  6. Ability to understand the study protocol and a willingness to sign a written informed consent document

Exclusion criteria

Exclusion Criteria:

  1. Patients with other kinds of cancer
  2. History of coagulation disorders or anemia
  3. Patients with heart disease and diabetes
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Group A

    DC-CIK cells will be used against tumor cells.

    Biological: DC-CIK

  • Experimental
    Group B

    γδ T cells will be used against tumor cells.

    Biological: γδ T Cell

  • Experimental
    Group C

    Combination of γδ T cells/ DC-CIK be used against tumor cells.

    Biological: γδ T/DC-CIK cells

Interventions

  • BiologicalDC-CIK

    DC-CIK cells will be used against tumor cells.

  • Biologicalγδ T Cell

    γδ T cells will be used against non small lung tumor.

  • Biologicalγδ T/DC-CIK cells

    γδ T/DC-CIK cells will be used against lung tumor.

06

What researchers measure

Primary outcomes

  1. Reduced size of the tumor.

    Time frame: Up to one year

07

Study locations

1 site
  • Biological treatment center in Fuda cancer hospital
    Guangzhou, Guangdong 510000, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02425748
Lead sponsor
Fuda Cancer Hospital, Guangzhou
Collaborators
Jinan University Guangzhou
Responsible party
Sponsor
First posted
Apr 24, 2015
Start date
Jun 8, 2017
Primary completion
Dec 20, 2017
Completion
Jun 20, 2019
Last update
Sep 12, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lung Neoplasms→

Other studies from this sponsor

Fuda Cancer Hospital, Guangzhou

Start the discussion